Private Profits versus Public Policy: The Pharmaceutical Industry and the Canadian State

By Joel Lexchin

© 2016

The widespread condemnation of drastic price increases on life-saving drugs highlights our growing dependency on and vulnerability to international pharmaceutical conglomerates. However, aren’t the interests of the public supposed to supersede the pursuit of private profit?

In his new work, Private Profits versus Public Policy, Joel Lexchin addresses this question as he examines how public policy with respect to the pharmaceutical industry has evolved in Canada over the past half century. Although the Canadian government is supposed to regulate the industry to serve the needs of public health, waves of deregulatory reforms and intellectual property rights legislation have shifted the balance of power in favour of these companies’ quest for profit.  Joel Lexchin offers a series of recommendations to tip the scale back in the public’s favour. This enlightening work is the first book that deals exclusively with the pharmaceutical industry in Canada in over thirty years.

Continue Reading Read Less

Product Details

  • World Rights
  • Page Count: 384 pages
  • Dimensions: 6.1in x 0.9in x 9.0in
Product Formats

SaveUP TO 9239

Book Formats

SKU# SP003905

  • PUBLISHED SEP 2016

    From: $26.96

    Regular Price: $35.95

    ISBN 9781442626591
  • PUBLISHED SEP 2016

    From: $59.25

    Regular Price: $79.00

    ISBN 9781442649170
  • PUBLISHED OCT 2016

    From: $26.96

    Regular Price: $35.95

Quick Overview

In his new work, Private Profits versus Public Policy, Joel Lexchin addresses this question as he examines how public policy with respect to the pharmaceutical industry has evolved in Canada over the past half century.

Private Profits versus Public Policy: The Pharmaceutical Industry and the Canadian State

By Joel Lexchin

© 2016

The widespread condemnation of drastic price increases on life-saving drugs highlights our growing dependency on and vulnerability to international pharmaceutical conglomerates. However, aren’t the interests of the public supposed to supersede the pursuit of private profit?

In his new work, Private Profits versus Public Policy, Joel Lexchin addresses this question as he examines how public policy with respect to the pharmaceutical industry has evolved in Canada over the past half century. Although the Canadian government is supposed to regulate the industry to serve the needs of public health, waves of deregulatory reforms and intellectual property rights legislation have shifted the balance of power in favour of these companies’ quest for profit.  Joel Lexchin offers a series of recommendations to tip the scale back in the public’s favour. This enlightening work is the first book that deals exclusively with the pharmaceutical industry in Canada in over thirty years.

Continue Reading Read Less

Product Details

  • World Rights
  • Page Count: 384 pages
  • Dimensions: 6.1in x 0.9in x 9.0in
  • Reviews

    "Joel Lexchin has written a very thorough overview of the Canadian history of public policy and the pharmaceutical industry. This work is a testament to the author’s standing as a world expert in this area."


    James McCormack, Faculty of Pharmaceutical Sciences, University of British Columbia

    "Private Profits versus Public Policy is a very interesting and well-referenced work. It offers a wealth of information in a field of work where hard information is difficult to gather."


    Nuria Homedes, School of Public Health, University of Texas
  • Author Information

    Joel Lexchin is a Fellow of the Canadian Academy of Health Sciences. He is a professor in the School of Health Policy and Management at York University and works as an emergency physician at the University Health Network.
  • Table of contents

    Abbreviations

    Boxes, Tables and Figures

    Introduction: Why do we care about the pharmaceutical industry in Canada?

    Chapter 1: (De)regulation through cooperation

    Chapter 2: Biased testing, hidden results and the regulation of clinical trials

    Chapter 3: Approving new drugs: better or just more?

    Chapter 4: Regulating promotion or licensing deception?

    Chapter 5: Health Canada and drug safety: how safe are we?

    Chapter 6: Is intellectual property a right?

    Chapter 7: How revenue is generated: prices, volume, mix and overall spending

    Chapter 8: Who gets the value from research and development?

    Chapter 9: Canada, the pharmaceutical industry and access to medicines in the Global South

    Chapter 10: Courage my friends; ’tis not too late to build a better world

    Acknowledgements

Related Titles